Advertisement

 

 

Imaging activated T cells predicts response to cancer vaccines.

Imaging activated T cells predicts response to cancer vaccines.
Author Information (click to view)

S Alam I, T Mayer A, Sagiv-Barfi I, Wang K, Vermesh O, K Czerwinski D, M Johnson E, L James M, Levy R, S Gambhir S,


S Alam I, T Mayer A, Sagiv-Barfi I, Wang K, Vermesh O, K Czerwinski D, M Johnson E, L James M, Levy R, S Gambhir S, (click to view)

S Alam I, T Mayer A, Sagiv-Barfi I, Wang K, Vermesh O, K Czerwinski D, M Johnson E, L James M, Levy R, S Gambhir S,

Advertisement

The Journal of clinical investigation 2018 03 29() doi 10.1172/JCI98509

Abstract

In situ cancer vaccines are under active clinical investigation due to their reported ability to eradicate both local and disseminated malignancies. Intratumoral vaccine administration is thought to activate a T cell mediated immune response, which begins in the treated tumor and cascades systemically. We describe a positron emission tomography tracer (64Cu-DOTA-AbOX40) that enabled non-invasive and longitudinal imaging of OX40, a cell surface marker of T cell activation. We report the spatiotemporal dynamics of T cell activation following in situ vaccination with CpG oligodeoxynucleotide, in a dual tumor bearing mouse model. We demonstrate that OX40 imaging could predict tumor responses at day 9 post treatment based on tumor tracer uptake at day 2, with higher accuracy than both anatomical and blood-based measurements. These studies provide key insights into global T cell activation following local CpG treatment and indicate that 64Cu-DOTA-AbOX40 is a promising candidate for monitoring clinical cancer immunotherapy strategies.

Submit a Comment

Your email address will not be published. Required fields are marked *

sixteen + fourteen =

[ HIDE/SHOW ]